JPRN-UMIN000006397招募中2 期
Phase II trial of XELOX plus bevacizumab for metastatic colorectal cancer. - N-SOG 06
agoya Surgical Oncology Group0 个研究点目标入组 50 人开始时间: 2011年10月1日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •(1)With brain metastases (2)Uncontrollable peptic ulcer disease (3)Prior chemotherapy with bevacizumab or oxaliplatin (4)Serious complications (5)Multiple malignancies to be treated (6)Severe neuropathy (7)With interstitial lung disease or pulmonary fibrosis (8)Pregnant (9)Previous history of severe drug-induced allergy (10)Disqualified by attending doctor
研究者
相似试验
招募中
2 期
Phase II trial of Bevacizumab with XELOX as an adjuvant treatment after resection of colorectal liver metastasesColorectal liver metastasesJPRN-UMIN000004352Tohoku University Graduate School of Medicine Division of Integrated Surgery and Oncology45
招募中
2 期
Phase II study of XELOX plus bevacizumab as second-line chemotherapy prior oral fluoropyrimidine,oxaliplatin plus bevacizumab for metastatic colorectal cancerJPRN-UMIN000011679Chubu Clinical Oncology Group25
已完成
2 期
Phase II study of XELOX plus bevacizumab as second-line chemotherapy prior oral fluoropyrimidine, irinotecan plus bevacizmab for metastatic colorectal cancernresectable metastatic or recurrent colorectal cancerJPRN-UMIN000011552Chubu Clinical Oncology Group (CCOG)25
已完成
2 期
Phase II trial of mFOLFOX6/XELOX plus bevacizumab with oxaliplatin in a stop and go fashion in advanced metastatic colorectal canceradvanced colorectal cancerJPRN-UMIN000002042Tohoku Clinical oncology, reserach and Education Society (T-CORE)65
已完成
2 期
To evaluate the efficacy of XELOX+Bevacizumab for patient with Metastatic Colorectal Cancer as second-line chemotherapycolorectal cancerJPRN-UMIN000003935Multicenter Study Group of Osaka (MCSGO), Colorectal Cancer Treatment Group48